

Erin Frazee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2872004/publications.pdf>

Version: 2024-02-01

79
papers

1,449
citations

430874

18
h-index

377865

34
g-index

80
all docs

80
docs citations

80
times ranked

1689
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function. <i>Clinical and Translational Science</i> , 2022, 15, 105-117.	3.1	7
2	Glomerular Function and Urinary Biomarker Changes between Vancomycin and Vancomycin plus Piperacillin-Tazobactam in a Translational Rat Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, aac0213221.	3.2	20
3	Early, biomarker-guided steroid dosing in COVID-19 Pneumonia: a pilot randomized controlled trial. <i>Critical Care</i> , 2022, 26, 9.	5.8	7
4	Incidence and Predictive Factors Associated with Beta-Lactam Neurotoxicity in the Critically Ill: A Retrospective Cohort Study. <i>Neurocritical Care</i> , 2022, 37, 73-80.	2.4	10
5	Development and Feasibility of a Multidisciplinary Approach to AKI Survivorship in Care Transitions: Research Letter. <i>Canadian Journal of Kidney Health and Disease</i> , 2022, 9, 205435812210812.	1.1	7
6	Nephrotoxin Exposure in the 3 Years following Hospital Discharge Predicts Development or Worsening of Chronic Kidney Disease among Acute Kidney Injury Survivors. <i>American Journal of Nephrology</i> , 2022, 53, 273-281.	3.1	7
7	Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder. <i>Journal of Personalized Medicine</i> , 2022, 12, 412.	2.5	7
8	Consensus Obtained for the Nephrotoxic Potential of 167 Drugs in Adult Critically Ill Patients Using a Modified Delphi Method. <i>Drug Safety</i> , 2022, 45, 389-398.	3.2	20
9	Optimising transitions of care for acute kidney injury survivors: protocol for a mixed-methods study of nephrologist and primary care provider recommendations. <i>BMJ Open</i> , 2022, 12, e058613.	1.9	1
10	Clinical Pharmacokinetics and Pharmacodynamics of Cefepime. <i>Clinical Pharmacokinetics</i> , 2022, 61, 929-953.	3.5	25
11	Angiotensin II Infusion for Shock. <i>Chest</i> , 2021, 159, 596-605.	0.8	41
12	Evaluation of the academic achievements of clinician health services research scientists involved in pre-career development award programs. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e122.	0.6	1
13	Poor Interrater Reliability of Retrospectively Applied Subjective Global Assessment for Malnutrition in the Critically Ill. <i>Topics in Clinical Nutrition</i> , 2021, 36, 13-22.	0.4	0
14	A Critical Appraisal of the Effects of Anesthetics on Immune-system Modulation in Critically Ill Patients With COVID-19. <i>Clinical Therapeutics</i> , 2021, 43, e57-e70.	2.5	6
15	Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate. <i>Supportive Care in Cancer</i> , 2021, 29, 5293-5301.	2.2	10
16	Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study. <i>Implementation Science Communications</i> , 2021, 2, 34.	2.2	8
17	Risk for Significant Kidney Function Decline After Acute Kidney Injury in Adults With Hematologic Malignancy. <i>Kidney International Reports</i> , 2021, 6, 1050-1057.	0.8	1
18	Development of a Theory-Informed Behavior Change Intervention to Reduce Inappropriate Prescribing of Nephrotoxins and Renally Eliminated Drugs. <i>Annals of Pharmacotherapy</i> , 2021, 55, 106002802110095.	1.9	2

#	ARTICLE	IF	CITATIONS
19	Including urinary output to define AKI enhances the performance of machine learning models to predict AKI at admission. <i>Journal of Critical Care</i> , 2021, 62, 283-288.	2.2	4
20	Impact of chloride-rich crystalloids on sepsis-associated community-acquired acute kidney injury recovery in critically ill patients. <i>Journal of Nephrology</i> , 2021, , 1.	2.0	0
21	Estimating renal function for drug dosing in critically ill patients with persistent inflammation, immunosuppression and catabolism syndrome. <i>Internal and Emergency Medicine</i> , 2021, 16, 1751-1753.	2.0	0
22	Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	1.3	1
23	Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?. , 2021, 3, e0446.		44
24	Stability and Validation of a High-Throughput LC-MS/MS Method for the Quantification of Cefepime, Meropenem, and Piperacillin and Tazobactam in Serum. <i>journal of applied laboratory medicine</i> , The, 2021, 6, 1202-1212.	1.3	10
25	The order of vasopressor discontinuation and incidence of hypotension: a retrospective cohort analysis. <i>Scientific Reports</i> , 2021, 11, 16680.	3.3	2
26	Estimation of Baseline Serum Creatinine with Machine Learning. <i>American Journal of Nephrology</i> , 2021, 52, 753-762.	3.1	4
27	Drug Excretion. , 2021, , .		3
28	Incidence of Serum Creatinine Monitoring and Outpatient Visit Follow-Up among Acute Kidney Injury Survivors after Discharge: A Population-Based Cohort Study. <i>American Journal of Nephrology</i> , 2021, 52, 817-826.	3.1	8
29	Nephrotoxins. , 2021, , 1-24.		0
30	Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. <i>Journal of Pharmacy Practice</i> , 2020, 33, 395-398.	1.0	8
31	Cost-effectiveness of second-line vasopressors for the treatment of septic shock. <i>Journal of Critical Care</i> , 2020, 55, 48-55.	2.2	12
32	Altered Pharmacokinetics and Dosing of Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation. <i>Pharmacotherapy</i> , 2020, 40, 89-95.	2.6	36
33	Effect of a multimodal multidisciplinary training program on pharmacy residents' knowledge and confidence toward research and biostatistics. <i>Currents in Pharmacy Teaching and Learning</i> , 2020, 12, 20-26.	1.0	8
34	Can NSAIDs Be Used Safely for Analgesia in Patients with CKD?: PRO. <i>Kidney360</i> , 2020, 1, 1184-1188.	2.1	1
35	Use of Cystatin C to Assess Immunotherapy Toxicity in a Patient With Melanoma. <i>Journal of Pharmacy Practice</i> , 2020, 35, 089719002096620.	1.0	0
36	Patterns of Cystatin C Uptake and Use Across and Within Hospitals. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1649-1659.	3.0	10

#	ARTICLE	IF	CITATIONS
37	Framework and Outcomes of a Critical Care Pharmacy Visiting Clinical Professor Program. , 2020, 2, e0137.		0
38	Management of Drug-Associated Acute Interstitial Nephritis. <i>Kidney360</i> , 2020, 1, 62-64.	2.1	6
39	Leveraging the Capabilities of the FDA's Sentinel System To Improve Kidney Care. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2506-2516.	6.1	8
40	Prediction of Vancomycin Levels Using Cystatin C in Overweight and Obese Patients: a Retrospective Cohort Study of Hospitalized Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	5
41	Predictors of Augmented Renal Clearance in a Heterogeneous ICU Population as Defined by Creatinine and Cystatin C. <i>Nephron</i> , 2020, 144, 313-320.	1.8	14
42	Cystatin C: A Primer for Pharmacists. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 35.	1.6	32
43	Quality of care after AKI development in the hospital: Consensus from the 22nd Acute Disease Quality Initiative (ADQI) conference. <i>European Journal of Internal Medicine</i> , 2020, 80, 45-53.	2.2	13
44	The professional sabbatical: A systematic review and considerations for the health-system pharmacist. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1632-1644.	3.0	6
45	Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. <i>Kidney International</i> , 2020, 98, 294-309.	5.2	254
46	Biomarker-Concordant Steroid Use in Critically Ill Patients with Pneumonia. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 649-656.	2.4	3
47	Clinician perspectives on inpatient cystatin C utilization: A qualitative case study at Mayo Clinic. <i>PLoS ONE</i> , 2020, 15, e0243618.	2.5	5
48	Validation of the sarcopenia index to assess muscle mass in the critically ill: A novel application of kidney function markers. <i>Clinical Nutrition</i> , 2019, 38, 1362-1367.	5.0	72
49	Incidence of Acute Kidney Injury Among Critically Ill Patients With Brief Empiric Use of Antipseudomonal β -Lactams With Vancomycin. <i>Clinical Infectious Diseases</i> , 2019, 68, 1456-1462.	5.8	59
50	Supplement Use by US Adults With CKD: A Population-Based Study. <i>American Journal of Kidney Diseases</i> , 2019, 74, 862-865.	1.9	4
51	Role of Loop Diuretic Challenge in Stage 3 Acute Kidney Injury. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1509-1515.	3.0	9
52	Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2271-2277.	1.3	8
53	Renal Recovery following Liposomal Amphotericin B-Induced Nephrotoxicity. <i>International Journal of Nephrology</i> , 2019, 2019, 1-8.	1.3	20
54	Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine: A Systematic Review. <i>Mayo Clinic Proceedings</i> , 2019, 94, 500-514.	3.0	42

#	ARTICLE	IF	CITATIONS
55	Quality Improvement Goals for Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 941-953.	4.5	152
56	Reply to letter regarding: "Validation of the sarcopenia index to assess muscle mass in the critically ill: A novel application of kidney function markers" <i>Clinical Nutrition</i> , 2019, 38, 1478.	5.0	0
57	Parenteral Nutrition Drug Shortages: A Single-Center Experience With Rapid Process Change. <i>Journal of Parenteral and Enteral Nutrition</i> , 2019, 43, 583-590.	2.6	4
58	PRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 288-302.	1.0	10
59	Baseline Thromboelastogram as a Predictor of Left Ventricular Assist Device Thrombosis. <i>ASAIO Journal</i> , 2019, 65, 443-448.	1.6	5
60	Sarcopenia Index Is a Simple Objective Screening Tool for Malnutrition in the Critically Ill. <i>Journal of Parenteral and Enteral Nutrition</i> , 2019, 43, 780-788.	2.6	38
61	Navigating the Muddy Waters of Vancomycin Nephrotoxicity. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1-3.	3.0	4
62	Relationship of Ganciclovir Therapeutic Drug Monitoring with Clinical Efficacy and Patient Safety. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	39
63	Prevention of Clostridium difficile Infection in Critically Ill Adults. <i>Pharmacotherapy</i> , 2019, 39, 399-407.	2.6	4
64	Impact of Acute Kidney Injury Following Diagnosis of Aggressive Lymphoma or Acute Leukemia on Long-Term Kidney Outcomes. <i>Blood</i> , 2019, 134, 1628-1628.	1.4	0
65	Impact of Preemptive Leucovorin Dose Escalation on Incidence of Delayed Methotrexate Elimination in Lymphoma Patients Receiving High-Dose Methotrexate. <i>Blood</i> , 2019, 134, 1621-1621.	1.4	0
66	The sarcopenia index: A novel measure of muscle mass in lung transplant candidates. <i>Clinical Transplantation</i> , 2018, 32, e13182.	1.6	64
67	Early Corticosteroids for Pneumocystis Pneumonia in Adults Without HIV Are Not Associated With Better Outcome. <i>Chest</i> , 2018, 154, 636-644.	0.8	58
68	Levetiracetam Pharmacokinetics in a Critically Ill Anephric Patient on Intermittent Hemodialysis. <i>Neurocritical Care</i> , 2018, 28, 243-246.	2.4	7
69	Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with) Tj ETQq1_1,0.784314 rgBT /D		
70	Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function. <i>Case Reports in Hematology</i> , 2018, 2018, 1-5.	0.4	8
71	It's What's Inside that Counts: Body Composition and Lung Transplantation. <i>Current Pulmonology Reports</i> , 2018, 7, 101-106.	1.3	0
72	Impact of Serum Cystatin C-Based Glomerular Filtration Rate Estimates on Drug Dose Selection in Hospitalized Patients. <i>Pharmacotherapy</i> , 2018, 38, 1068-1073.	2.6	12

#	ARTICLE	IF	CITATIONS
73	Innovative Use of Novel Biomarkers to Improve the Safety of Renally Eliminated and Nephrotoxic Medications. <i>Pharmacotherapy</i> , 2018, 38, 794-803.	2.6	35
74	β ² -Lactams: The Competing Priorities of Nephrotoxicity, Neurotoxicity, and Stewardship. <i>Annals of Pharmacotherapy</i> , 2018, 52, 1167-1168.	1.9	4
75	Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project. <i>American Journal of Kidney Diseases</i> , 2017, 69, 658-666.	1.9	60
76	Clinical Relevance and Predictive Value of Damage Biomarkers of Drug-Induced Kidney Injury. <i>Drug Safety</i> , 2017, 40, 1049-1074.	3.2	22
77	Cystatin C Falsely Underestimated GFR in a Critically Ill Patient with a New Diagnosis of AIDS. <i>Case Reports in Nephrology</i> , 2016, 2016, 1-4.	0.4	4
78	Fluid Management for Critically Ill Patients: A Review of the Current State of Fluid Therapy in the Intensive Care Unit. <i>Kidney Diseases (Basel, Switzerland)</i> , 2016, 2, 64-71.	2.5	27
79	Vancomycin should be considered a nephrotoxic antimicrobial agent: PRO. <i>Kidney360</i> , 0, , 10.34067/KID.0008032021.	2.1	0